Summary & Overview
CPT 87651: Streptococcus Group A Detection by Nucleic Acid Amplification
CPT code 87651 represents a laboratory test for the detection of group A Streptococcus using nucleic acid (DNA or RNA) amplified probe technique. This test is a critical tool in diagnosing streptococcal infections, such as pharyngitis and tonsillitis, which are prevalent across the United States. The code is widely recognized and reimbursed by major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare, reflecting its importance in clinical practice and coverage policies.
This publication provides a comprehensive overview of 87651, including payer coverage, clinical context, and related coding benchmarks. Readers will gain insight into the laboratory service's role in infectious disease diagnostics, typical sites of service, and how it compares to related CPT codes for Streptococcus testing. The summary also highlights relevant modifiers and associated taxonomies, offering a clear understanding of the code's application in both laboratory and physician settings. Policy updates and coding trends are discussed to inform stakeholders about current practices and reimbursement considerations. The information is designed for a national audience, supporting healthcare professionals, billing specialists, and policy analysts in navigating the complexities of laboratory coding and coverage.
CPT Code Overview
CPT code 87651 is used for the detection of Streptococcus, group A, through nucleic acid (DNA or RNA) amplified probe technique. This laboratory service is typically performed in a clinical laboratory setting, designated as Place of Service 81. The procedure is essential for identifying group A Streptococcus infections, which are commonly associated with conditions such as pharyngitis and tonsillitis. The use of nucleic acid amplification provides a highly sensitive method for detecting the presence of the infectious agent, supporting timely and accurate diagnosis.
Clinical & Coding Specifications
Clinical Context
A patient, typically a child or adolescent, presents to a primary care clinic or urgent care with symptoms such as sore throat, fever, and difficulty swallowing. The provider suspects a streptococcal infection based on clinical assessment. A throat swab is collected and sent to a clinical laboratory (Place of Service 81) for testing. The laboratory performs nucleic acid amplification to detect Streptococcus, group A, using CPT code 87651. The results assist the provider in confirming or ruling out streptococcal pharyngitis or tonsillitis, guiding further management.
Coding Specifications
Common Modifiers:
-
Modifier
59: Distinct Procedural Service. Used when the procedure is performed separately from other services, indicating it is not part of a bundled service. -
Modifier
91: Repeat Clinical Diagnostic Laboratory Test. Used when the same laboratory test is repeated on the same patient on the same day to obtain additional information.
Associated Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
291U00000X | Clinical Medical Laboratory |
207Q00000X | Family Medicine Physician |
207R00000X | Internal Medicine Physician |
These taxonomies represent the clinical laboratory performing the test and the physicians who may order the test.
Related Diagnoses
-
J02.0— Streptococcal pharyngitis: Indicates infection of the pharynx caused by group A Streptococcus; primary reason for ordering CPT code87651. -
J03.00— Acute streptococcal tonsillitis, unspecified: Represents acute infection of the tonsils by group A Streptococcus; relevant for laboratory confirmation. -
J02.9— Acute pharyngitis, unspecified: Used when pharyngitis is present but the causative agent is not yet identified; laboratory testing helps determine etiology. -
J03.90— Acute tonsillitis, unspecified: Indicates acute tonsillitis without specified cause; testing assists in identifying Streptococcus as the agent. -
R07.0— Pain in throat: Symptom code for throat pain; may prompt testing to rule out streptococcal infection.
Related CPT Codes
| CPT Code | Description | Clinical Relationship |
|---|---|---|
87880 | Infectious agent antigen detection by immunoassay with direct optical observation; Streptococcus, group A | Alternative rapid antigen test for group A Streptococcus; often used in initial screening. |
87070 | Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates | Used for bacterial culture when confirmation or broader identification is needed; may follow negative rapid tests. |
87430 | Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple-step method; Streptococcus, group A | Another method for antigen detection; alternative to nucleic acid or direct immunoassay techniques. |
87500 | Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, direct probe technique | Used for detection of influenza virus; may be ordered concurrently if viral etiology is suspected. |
Codes 87880, 87430, and 87070 are commonly used as alternatives or adjuncts to 87651 in the diagnostic workflow for suspected streptococcal infection. 87500 is used for influenza testing, which may be considered in patients with similar symptoms.
National Reimbursement Benchmarks
National mean rates for CPT code 87651 show that Blue Cross Blue Shield, Cigna, Aetna, UnitedHealth Group, and BUCA (average commercial) all reimburse at levels above typical Medicare rates, though Medicare data is not available in the input for direct comparison. Among commercial payers, Aetna and Cigna have the highest mean rates, both near $39.50, while Blue Cross Blue Shield is notably lower at $30.55.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies across payers. Cigna exhibits the widest spread ($48.00 - $21.00 = $27.00), indicating greater variability in rates. Blue Cross Blue Shield has the tightest range ($35.00 - $21.29 = $13.71), suggesting more consistent reimbursement levels. The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.